메뉴 건너뛰기




Volumn 2, Issue 11, 2017, Pages 771-772

Shortening HCV therapy: science meets public health

Author keywords

[No Author keywords available]

Indexed keywords

ELBASVIR; GRAZOPREVIR; PROTEINASE INHIBITOR; RUZASVIR; UPRIFOSBUVIR;

EID: 85032257014     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(17)30215-7     Document Type: Note
Times cited : (2)

References (9)
  • 1
    • 85025098013 scopus 로고    scopus 로고
    • World Health Organization Geneva
    • WHO. Global hepatitis report 2017, 2017, World Health Organization, Geneva.
    • (2017) Global hepatitis report 2017
  • 2
    • 84962280759 scopus 로고    scopus 로고
    • Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens
    • Wilson, EM, Kattakuzhy, S, Sidharthan, S, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis 62 (2016), 280–288.
    • (2016) Clin Infect Dis , vol.62 , pp. 280-288
    • Wilson, E.M.1    Kattakuzhy, S.2    Sidharthan, S.3
  • 3
    • 85013287732 scopus 로고    scopus 로고
    • Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection
    • Koizumi, Y, Ohashi, H, Nakajima, S, et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci USA 114 (2017), 1922–1927.
    • (2017) Proc Natl Acad Sci USA , vol.114 , pp. 1922-1927
    • Koizumi, Y.1    Ohashi, H.2    Nakajima, S.3
  • 4
    • 84995756438 scopus 로고    scopus 로고
    • Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
    • Lau, G, Benhamou, Y, Chen, G, et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 1 (2016), 97–104.
    • (2016) Lancet Gastroenterol Hepatol , vol.1 , pp. 97-104
    • Lau, G.1    Benhamou, Y.2    Chen, G.3
  • 5
    • 85032275643 scopus 로고    scopus 로고
    • Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in patients without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials
    • published online Aug 9.
    • Gane, EJ, Pianko, S, Roberts, SK, et al. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in patients without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30159-0.
    • (2017) Lancet Gastroenterol Hepatol
    • Gane, E.J.1    Pianko, S.2    Roberts, S.K.3
  • 6
    • 85032295255 scopus 로고    scopus 로고
    • Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in patients with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
    • published online Aug 9.
    • Lawitz, E, Buti, M, Vierling, JM, et al. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in patients with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30163-2.
    • (2017) Lancet Gastroenterol Hepatol
    • Lawitz, E.1    Buti, M.2    Vierling, J.M.3
  • 7
    • 84925607745 scopus 로고    scopus 로고
    • Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
    • Kohli, A, Osinusi, A, Sims, Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 385 (2015), 1107–1113.
    • (2015) Lancet , vol.385 , pp. 1107-1113
    • Kohli, A.1    Osinusi, A.2    Sims, Z.3
  • 8
    • 85032264529 scopus 로고    scopus 로고
    • Shortening the duration of therapy for chronic hepatitis C infection
    • published online Aug 9.
    • Emmanuel, B, Wilson, EM, O'Brien, TR, Kottilil, S, Lau, G, Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30053-5.
    • (2017) Lancet Gastroenterol Hepatol
    • Emmanuel, B.1    Wilson, E.M.2    O'Brien, T.R.3    Kottilil, S.4    Lau, G.5
  • 9
    • 84938751694 scopus 로고    scopus 로고
    • Modelling hepatitis C therapy-predicting effects of treatment
    • Perelson, AS, Guedj, J, Modelling hepatitis C therapy-predicting effects of treatment. Nat Rev Gastroenterol Hepatol 12 (2015), 437–445.
    • (2015) Nat Rev Gastroenterol Hepatol , vol.12 , pp. 437-445
    • Perelson, A.S.1    Guedj, J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.